JILIN AODONG(SZ:000623)2022-11-11 02:41Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1957 and transformed into a joint-stock company in March 1993, listed on the Shenzhen Stock Exchange in October 1996 [2] - The company operates in the pharmaceutical manufacturing industry, focusing on modern traditional Chinese medicine, biochemical drugs, and health food products [2][3] - As of June 30, 2022, the company had 51 products under research and 18 major products undergoing secondary development [3] Group 2: Financial Performance - The company's net assets reached CNY 2,491,786.93 million, an increase of CNY 5,838.07 million from the beginning of the year, representing a year-on-year growth of 0.23% [3] - The asset-liability ratio stood at 14.55% [3] - The company achieved operating revenue of CNY 125,023.26 million, an increase of CNY 16,748.61 million from the previous year, reflecting a year-on-year growth of 15.47% [3] Group 3: Investment Activities - The company became the largest shareholder of GF Securities, holding 1,448,016,667 shares, which accounts for 19.0001% of GF Securities' total share capital as of July 31, 2022 [3] - It also holds a 5.00% stake in Liaoning Chengda, making it the fourth largest shareholder [3] - The company has invested in various pharmaceutical companies and established a fund with GF Xinde to invest in promising pharmaceutical enterprises [3] Group 4: Strategic Partnerships and Product Launches - Jilin Aodong has partnered with XinXuan Group, a digital new retail enterprise, to enhance its supply chain and retail capabilities [3] - On September 15, 2022, the company launched five new products, including fish oil soft capsules, during a strategic upgrade event [3] - The company reported a GMV of approximately CNY 25,906 million from a live-streaming event promoting its new products [3] Group 5: Future Development Strategy - The company aims to leverage its resources in the Yanbian region and the Changbai Mountain area to enhance its pharmaceutical offerings [3] - It plans to focus on R&D investment and accelerate the transformation of technological achievements to meet consumer demands [3] - The goal is to establish itself as a leading brand in the domestic health sector [3]